FDA Approves App to Help Guide MS Patient Care with Betaseron

The myBETAapp and BETACONNECT Navigator get FDA approval
The myBETAapp and BETACONNECT Navigator get FDA approval

Bayer announced that the Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for myBETAapp and the BETACONNECT Navigator for use in patients with relapsing-remitting multiple sclerosis (MS).

This new software allows patients currently using the electronic BETACONNECT autoinjector to administer Betaseron (interferon beta-1b) to connect their autoinjector to the new myBETAapp through their mobile device or computer. Patient injection data can be shared with their BETA Nurse and healthcare team; this allows the team to track injection history and provide support to patients through the BETACONNECT Navigator. 

Related Articles

MS patients who administer Betaseron by other injection methods can still enter their data into the myBETAapp and share it with their BETA Nurse and healthcare team. 

Betaseron, an interferon beta, is currently indicated to treat relapsing forms of MS to reduce the frequency of clinical exacerbations. It is available as a lyophilized powder in 3mL single-use vials in 5-count cartons.  The optional BETACONNECT autoinjector is not supplied with Betaseron, but is available for patients with a prescription for Betaseron by calling the BETAPLUS patient support program at (800) 788-1467. The myBETAapp will be available as a free download in mid-July.

For more information call (800) 788-1467 or visit Betaseron.com.